Hour24 News
Sophisticated and simple
-
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring…
-
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated…
-
Overview New real‑world data from the 2024-2025 RSV season indicate that nirsevimab, a monoclonal antibody given to infants to prevent severe respiratory syncytial virus (RSV)…
